Beacon Pharmaceuticals Income Statement

Financials in millions BDT. Fiscal year is July - June.

Millions BDT. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Revenue	14,785	12,543	10,702	8,510	8,023	7,121
Revenue Growth (YoY)	27.69%	17.20%	25.75%	6.07%	12.66%	27.37%
Cost of Revenue	7,212	6,072	5,215	4,251	3,906	3,452
Gross Profit	7,573	6,471	5,487	4,259	4,116	3,669
Selling, General & Admin	4,849	4,137	3,672	3,295	2,499	2,307
Other Operating Expenses	-	-	-	-14.86	-	-
Operating Expenses	4,849	4,137	3,672	3,280	2,499	2,307
Operating Income	2,724	2,334	1,814	979.12	1,617	1,362
Interest Expense	-1,327	-1,308	-1,003	-460.92	-337.96	-164.82
Interest & Investment Income	330.78	330.78	227.86	155.13	0.32	3.24
Currency Exchange Gain (Loss)	-73.24	-73.24	-93.69	2.68	0.5	-
Other Non Operating Income (Expenses)	57.32	17.79	13.85	-	9.81	-1.98
EBT Excluding Unusual Items	1,712	1,301	959.82	676.01	1,290	1,198
Gain (Loss) on Sale of Assets	-0.01	-0.01	-6.5	3.07	3.04	-
Pretax Income	1,712	1,301	953.32	679.07	1,293	1,198
Income Tax Expense	474.12	354.53	432.31	169.23	357.93	334.99
Net Income	1,238	946.51	521.01	509.84	935.04	863.17
Net Income to Common	1,238	946.51	521.01	509.84	935.04	863.17
Net Income Growth	117.11%	81.67%	2.19%	-45.47%	8.33%	126.74%
Shares Outstanding (Basic)	231	231	231	231	231	231
Shares Outstanding (Diluted)	231	231	231	231	231	231
EPS (Basic)	5.36	4.10	2.26	2.21	4.05	3.74
EPS (Diluted)	5.36	4.10	2.26	2.21	4.05	3.74
EPS Growth	117.11%	81.67%	2.19%	-45.47%	8.33%	126.74%
Free Cash Flow	726.84	778.5	-1,275	-1,193	-637.07	-116.85
Free Cash Flow Per Share	3.15	3.37	-5.52	-5.17	-2.76	-0.51
Dividend Per Share	2.100	2.100	2.000	1.600	1.600	1.500
Dividend Growth	5.00%	5.00%	25.00%	-	6.67%	-
Gross Margin	51.22%	51.59%	51.27%	50.05%	51.31%	51.52%
Operating Margin	18.42%	18.61%	16.96%	11.51%	20.16%	19.12%
Profit Margin	8.37%	7.55%	4.87%	5.99%	11.65%	12.12%
Free Cash Flow Margin	4.92%	6.21%	-11.91%	-14.02%	-7.94%	-1.64%
EBITDA	3,407	2,966	2,342	1,498	2,057	1,747
EBITDA Margin	23.04%	23.64%	21.89%	17.60%	25.64%	24.53%
D&A For EBITDA	683.21	631.4	527.78	518.92	439.7	385.16
EBIT	2,724	2,334	1,814	979.12	1,617	1,362
EBIT Margin	18.42%	18.61%	16.96%	11.51%	20.16%	19.12%
Effective Tax Rate	27.70%	27.25%	45.35%	24.92%	27.68%	27.96%
Advertising Expenses	-	83.97	72.55	69.04	68.5	52.97

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.